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Abstract  
 
Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, 
complete response rates remain relatively low and outcomes in other cancers are less 
impressive. The immunosuppressive nature of the tumor microenvironment and the 
expression of immune-inhibitory ligands, such as PD-L1/CD274 by the tumor and 
stroma are considered key factors limiting efficacy. The addition of checkpoint 
inhibitors (CPI) to ACT protocols bypasses some mechanisms of immunosuppression, 
but associated toxicities remain a significant concern. To overcome PD-L1-mediated 
immunosuppression and reduce CPI-associated toxicities, we used TALEN 
technology to render tumor-reactive T cells resistant to PD-1 signaling. Here we 
demonstrate that inactivation of PD-1 in melanoma-reactive CD8+ T cells and in 
fibrosarcoma-reactive polyclonal T cells enhanced the persistence of PD-1 gene-
modified T cells at the tumor site and increased tumor control. These results illustrate 
the feasibility and potency of approaches incorporating advanced gene-editing 
technologies into ACT protocols to silence immune checkpoints, as a strategy to 
overcome locally active immune escape pathways. 
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Introduction  
Adoptive T cell therapy (ACT) using autologous tumor-infiltrating lymphocytes 
(TILs) or T cells redirected to the tumor by chimeric antigen receptors (CARs) can 
mediate substantial regression of human cancers (1). Whilst multiple early-phase 
studies using ACT have demonstrated durable responses which correlate with 
persistence of the transferred T cells (2, 3), their in vivo activity and potency can be 
thwarted by the complex immunosuppressive nature of the tumor microenvironment 
(4). Combination protocols incorporating checkpoint inhibitors (CPIs) such as anti-
CTLA-4 or anti-PD-L1/PD-1 are currently being considered (NCT02408861; 
NCT02210117; NCT02374242; NCT02453620) but the potential exacerbation of the 
toxicities associated with CPIs may limit their implementation. Advanced genetic 
engineering of the ACT product offers a solution to the toxicity issues by specifically 
targeting tumor-reactive T cells rather than inducing systemic blockade of the 
inhibitory checkpoint. The protocols used for the generation of ACT are compatible 
with genetic manipulation of cells prior to transfer, which can be used to increase the 
proliferative capacity of lymphocytes (5), to prolong their in vivo persistence (6), to 
improve tumor infiltration (7) as well as to bypass tumor immune suppression.  
Programmed Death-1 (PD-1, CD279) is one of the key co-inhibitory immune 
receptors expressed by activated T cells. Initially described on a T cell hybridoma 
undergoing cell death (8), PD-1 is a critical regulator of T cell responses and essential 
to the maintenance of peripheral self-tolerance (9). In mouse and human cancers, high 
levels of PD-1 are found on TILs, whilst its ligand (PD-L1) is upregulated by tumor 
and stromal cells in response to inflammatory cytokines (e.g. IFN-γ  (10, 11). The 
PDL-1/PD-1 axis plays a major role in tumor growth and immune escape through 
inhibition of T cell proliferation, effector function (12) and of T cell survival by 
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promotion of apoptosis (13). The administration of blocking anti-PD-1 or PDL-1 
antibodies in vivo results in enhanced CD8+ T cell responses and decreases tumor 
burden in mouse models of cancer (14, 15). In humans, expression of PD-1 by TILs is 
associated with impaired effector function and/or poor outcome in several tumor types 
(16, 17). Direct evidence supporting the importance of this pathway in modulating 
antitumor immunity comes from recent clinical trials in melanoma and non small cell 
lung cancer, where anti-PD-1 antibodies have improved both progression free and 
overall survival (18, 19). Of relevance, systemic immunotherapy with CPIs can also 
induce immune-related adverse events (irAEs). Specific ablation of negative 
regulators of T-cell function on tumor-reactive T cells used for ACT offers the 
potential to exploit the antitumor activity whilst reducing systemic toxicity.  
Efficient and rapid inactivation of genes in primary antigen-specific T cells is 
achievable using the transient expression of transcription activator-like effector 
nucleases (TALEN) mRNA, which offers several safety advantages for clinical 
applications (20). Using two different mouse models of cancer, we defined the impact 
of TALEN-mediated PD-1 gene inactivation in adoptively transferred tumor-reactive 
CD4+ and CD8+ T cells. Our data supports a model in which PD-1 gene inactivation 
increases persistence of T cells at the tumor site, enhancing tumor control of B16 
melanoma by gp-100-reactive CD8+ T cells and mediating complete rejection of 
established MCA205 fibrosarcoma by endogenous CD4+ and CD8+ T cells. This work 
demonstrates both the feasibility and the potential potency of strategies incorporating 
Immune Checkpoint Editing (ICE) of tumor-reactive T cells for use in the context of 
adoptive T cell therapies for cancer. 
 
 
 5 
Materials and Methods  
Mice and cell lines 
6- to 8-week-old pmel-1/SJL TCR-transgenic, C57BL/6 and C57BL/6-SJL mice were 
purchased from Charles River Laboratories Kent. All animal use was in accordance 
with the Home Office guidelines. The B16.BL6 melanoma cell line was obtained 
from Prof James Allison, the MCA205 fibrosarcoma cell line was provided by Prof 
Guido Kroemer, EL4 thymoma cells were provided by Prof Henning Walczak and 
authentication was performed by the ATCC using short tandem repeat DNA profiles. 
The cells were grown in RPMI-1640 supplemented with 10% FCS, L-glutamine, 
Pen/Strept (Sigma-Aldrich). 
TALEN construction and validation  
Three pairs of TALEN targeting the PD-1 murine gene were produced by Cellectis 
using the solid phase assembly method (21). Their activity was evaluated in 5x106 
EL4 cells, co-transfected with 10 μg of in vitro transcribed mRNA (mMESSAGE 
mMACHINE T7 Kit, Ambion) from each half TALEN (Fig. S1). Three days post 
transfection, locus specific PCRs were performed on genomic DNA. (Table S1), 
mutations were assessed by mismatches digestion (T7) and Miseq analysis (20).  
Cell culture and adoptive transfer 
Splenocytes and lymph nodes cells from pmel-1/SJL transgenic mice were cultured in 
complete RPMI with gp100 peptide (Pepceuticals) and rhIL-2 (Preprotech) 100UI/mL 
for 24h prior to selection of CD8+ T cells using Dynabeads FlowComp Mouse CD8 
kit. TRL were selected from 100-150mm3 tumors using Dynabeads FlowComp Mouse 
Pan T (CD90.2) and maintained in complete RPMI with rhIL-2 (1000UI/mL). 5x106 
Pmel-1 CD8+ T cells and MCA205 TRL/180 μL of BTX medium T were mixed with 
20 μg of IVT mRNA, prior to electroporation using an Agile Pulse BTX system 
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(Harvard Apparatus). C57BL/6 mice were subcutaneously implanted with either 
2.5x105 B16 cells or 4x105 MCA205 cells (day 0). On day 6 for the pmel-1 model and 
on day 4 for the MCA205 model, total body irradiation (TBI) was performed (5 Gy) 
and 1x106 pmel-1 T cells or 1x106 MCA205 TRL were adoptively transferred into 
tumor-bearing mice (n = 5 per group), followed by intraperitoneal (i.p.) injection of 
rhIL-2 (1.2x106 IU) for 3 days. Mice were sacrificed when the tumors exceeded 15 
mm in diameter. Mice were treated with the anti-mouse CD8a 2.43 depleting antibody 
(BioXcell) and the anti-MCH class II M5/114 (BioXcell), i.p. on day 0, 2, 4, 6, 8 after 
ACT (10 mg/kg).   
Flow cytometry  
Tumors were weighed, digested in collagenase D (Roche) and mechanically 
disaggregated through 70-μm filters. Lymph nodes cells and lymphocytes from tumor 
samples, enriched on a Ficoll gradient were incubated with murine antibodies: anti-
CD4-V500 (BD Horizon), anti-CD8-BV650, anti-PD-1-PE-Cy7 (Biolegend), anti-
CD45.1-APC-Cy7, anti-FoxP3-AF700, anti-IFN-γ-FITC (re-stimulation with gp100-
pulsed dendritic cells for pmel cells or PMA/ionomycin for TRL), anti-KI67-PerCP-
eFluor 710, Fixable Viability Dye eFluor 450 (eBioscience), anti-FLICA (Vybrant 
FAM Poly Caspases Assay Kit, ThermoFisher), annexin-V-PE Apoptosis Detection 
Kit II (BD Pharmingen), Cell Sorting Set-up Beads (Life Technologies), and anti-
human Granzyme B-APC (Invitrogen) in a blocking solution: 5% mouse serum, 5% 
rat serum (Thermoscientific), 2% FCS, 2% anti-FcR 2.4G2 (BioXcell). Samples were 
permeabilized using a Fixation/Permeabilization kit (eBioscience), acquired on a 
LSRII Fortessa and analysed with FlowJo software (Tree-Star). 
Western blot analysis 
Proteins were separated and subjected to the following antibodies: anti-TALEN 
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(1mg/ml), anti-GAPDH (D16H11) (Cell signaling, 1:2000), HRP-coupled secondary 
antibody anti-Rabbit IgG1 HRP-linked (Cell signaling).  
Statistical analysis  
One-way ANOVA, two-way ANOVA or t tests with P < 0.05 were performed using 
Prism 6.0 software (GraphPad). Multiple comparisons were corrected with the 
Bonferroni coefficient and Kaplan-Meier survival curves were compared with the log-
rank test.  
For additional information, see supplemental data section 
Results and Discussion  
TALEN-mediated PD-1 gene inactivation in melanoma reactive CD8+ pmel-1 T 
cells increases persistence of CD8PD-1Ex1 pmel-1 cells at the tumor site  
Three pairs of TALENs targeting the murine PD-1 gene were tested in EL4 cells 
using an optimized mRNA-electroporation protocol. Only the pair targeting the exon 
1 sequence (Fig. 1A) caused detectable mismatch-identified mutagenesis (up to 27%) 
in the PD-1 gene, correlating with loss of PD-1 expression in up to 15% of 
electroporated EL4 cells (Supplementary Fig. S1). To investigate whether PD-1 
inactivation of primary tumor-reactive T cells provided superior antitumor activity 
against the poorly immunogenic mouse melanoma B16 model, we used CD8+ T cell 
receptor transgenic (TCR Tg) cells specific to the melanoma differentiation antigen 
gp-100 (pmel-1, Supplementary Fig. S2A) (22). In vitro activated pmel-1 T cells were 
electroporated with control GFP mRNA (CD8wt) or PD-1-targeting TALEN mRNA 
(CD8PD-1Ex1), delivering a high transfection efficiency of >85% as confirmed by GFP 
expression (Supplementary Fig. S2B). Western blot analysis confirmed transient 
TALEN expression one day (d1) after transfection (Fig.1B) and Miseq analysis of the 
targeted sequence showed a high frequency of mutations (53% non-homologous end 
 8 
joining (NHEJ)) (Fig. 1C). Three days after transfection, PD-1 negative cells were 
enriched using magnetic beads (Supplementary Fig. S2C) prior to ACT of 1x106 
CD8wt or CD8PD-1Ex1 pmel-1 cells and rhIL-2 into B16 tumor-bearing mice. 
Significantly enhanced tumor control was consistently observed in mice receiving 
CD8PD-1Ex1 cells compared to those treated with CD8wt cells (Fig. 1D). Six days after 
transfer in vivo, a significant enrichment of tumor-infiltrating PD-1 negative pmel-1 
cells was observed in mice treated with CD8PD-1Ex1 T cells (48.2%) (Fig. 1E upper 
panel), which contributed to a 2-fold increase in the total number of tumor-infiltrating 
pmel-1 cells (Fig. 1E lower panel). In contrast,, the absolute number of T cells in 
draining lymph nodes (DLNs) was similar between the two groups, suggesting that 
accumulation of CD8PD-1Ex1 T cells at the tumor site was not due to differences in 
engraftment nor infiltration from the DLNs (Supplementary Fig. S2D). Whereas use 
of RNA and electroporation to deliver TALENs is compatible with future clinical 
translation, it does not allow incorporation of a reporter gene to distinguish PD-1 
edited cells. Nevertheless, the rate of mutagenesis, investigated ex-vivo 7 days after 
ACT demonstrates an effective PD-1 gene editing (70%) in the PD-1 negative 
fraction from the CD8PD-1Ex1 group (Supplementary Fig. S2E). To investigate the 
mechanisms underpinning enhanced tumor control by pmel-1 cells in the CD8PD-1Ex1 
group, we characterized the proliferation and effector functions of CD8wt and CD8PD-
1Ex1 T cells in both PD-1+ and PD-1- tumor-infiltrating pmel-1 populations.  Contrary 
to previous work suggesting that PD-1 signaling reduces effector activity at the tumor 
site (23), no differences were observed in KI67, granzyme B (GZB) or interferon-γ 
(IFN-γ) expression between PD-1+ and PD-1- cells. When we compared the adjusted 
percentages (% of cells in PD-1+ and PD-1- sub-populations) of tumor-infiltrating 
KI67+, GZB+ and IFN-γ+ cells, we observed that the TALEN-induced PD-1 gene 
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inactivation did not impact the proliferative or functional characteristics of pmel-1 
CD8+T cells in vivo (Supplementary Fig. S2F, G, H). Instead, we consistently 
observed the appearance of a PD-1- pmel-1 population in the CD8PD-1Ex1 group, which 
contributed to an increase in the total number of KI67-, GZB- and IFN-γ -expressing 
cells in tumors from mice receiving CD8PD-1Ex1 T cells (Fig. 1F, G). Together these 
data strongly suggest that, at least in the context of ACT, PD-1 expression primarily 
controls number of tumor-reactive T cells at the tumor site rather than their 
proliferative or functional status.  
PD-1 gene inactivation of polyclonal tumor-reactive lymphocytes (TRL) 
promotes persistence of activated CD4+ and CD8+ at the tumor site 
To define the therapeutic potential and functional impact of PD-1 gene inactivation in 
a more physiologically relevant T cell population, we conducted the PD-1 gene 
editing of polyclonal tumor-reactive lymphocytes (TRL) from C57BL/6SJL mice, 
challenged with MCA205 cells (24). CD4+ and CD8+ T-cells were isolated from the 
tumor (TILs) and one tumor-draining lymph node (TDLN) via positive selection. 
After electroporation of the donor TRL, we observed a transfection efficiency >65% 
and we identified TALEN-induced PD-1 gene mutations by Miseq analysis in 26% of 
CD4+ T cells and almost 40% of CD8+ T cells (Supplementary Fig. S3A, B).  
In parallel to the generation of the donor mock transfected (TRLwt) and PD-1 edited 
TRL cells (TRLPD-1Ex1), we challenged a separate group of C57BL/6 mice with 
MCA205 tumors. Four days later, tumor-bearing mice were treated with TBI followed 
by ACT with TRLwt or TRLPD-1Ex1 cells and rhIL-2. Six days after transfer, analysis of 
PD-1 expression on TILs from mice receiving TRLwt or TRLPD-1EX1 revealed a 15-
20% average increase in PD-1- CD4+ and PD-1- CD8+ T cells (Fig. 2A, B). Consistent 
with our findings in the TCR Tg model, a significant accumulation of PD-1- cells was 
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observed only at the tumor site (Fig. 2C, S3C). Whilst PD-1 gene inactivation did not 
alter TRL proliferation (KI67) or function (GZB and IFN-γ) (Supplementary Fig. 
S3D, E, F), the absolute number of PD1- TRL expressing KI67, GZB and IFN-γ was 
significantly higher in mice receiving TRLPD-1EX1 (Fig. 2D, E, F).  
Given that the increase in the number of PD-1- cells in mice receiving TRLPD-1EX1 
cells was not associated with increased proliferation, we evaluated whether this could 
be explained by a reduced rate of PD-1-induced death. Using annexin-V and a 
fluorescent caspase substrate kit (FLICA), we observed an overall reduction in the 
frequency of intra-tumoral apoptotic cells in PD-1-compared to PD-1+ CD4+ and 
CD8+ T cells (Fig. 3A, B, D, E). Whereas we observed no difference in the frequency 
of apoptotic cells between mice treated with TRLwt and TRLPD-1EX1, a significant 
increase in the absolute number of annexin-V- and FLICA- TRLPD-1EX1cells per mg of 
tumor was reported (Fig. 3C, F). The data suggest that instead of increasing T cell 
reactivity against tumors, TRLPD-1EX1 cells are rendered resistant to PD-1-mediated 
cell death at the tumor site.  
PD-1 gene-inactivation drives CD4 and CD8 dependent rejection of established 
tumors and long-term memory 
PD-1-gene inactivation significantly increased the activity of our ACT protocol 
(p=0.0052) and anti-tumor activity was dependent on both CD8+ and CD4+ T cells as 
administration of depleting anti-CD8 or MHC-II blocking antibodies ablated anti-
tumor responses (Fig. 4A, B). No evidence of tumor recurrence was observed after 
MCA205 rechallenge on day 50 in mice that had previously rejected tumors (data not 
shown). The development of long-term memory, as demonstrated by protection 
against a subsequent tumor challenge, is an important feature of successful T cell 
adoptive immunotherapy (25). Our data show high levels of KI67, consistent with 
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high proliferative capacity for both TRL and TRLPD-1EX1 cells, which also displayed a 
T-bethi CD62LlowCD44hi phenotype consistent with effector memory T cells 
(Supplementary Fig. S4A,B) (27). Finally, ex-vivo stimulation of circulating T cells 
from surviving mice (40 days after tumor rejection) demonstrated high levels of IFN- 
production in both TRL and TRLPD-1EX1 groups arguing against terminal 
differentiation (Supplementary Fig. S4C) (28). 
In summary, our data demonstrate the feasibility of application of clinically relevant 
gene-editing approaches, conferring superior in vivo activity in the context of 
adoptive cell therapy protocols. In both tumor models, mice well tolerated the ACT 
with no evidence of toxicity (weight, physiological alterations). To the best of our 
knowledge this is the first proof of concept study illustrating enhancement and 
persistence of antitumor responses using targeted genome editing of primary tumor 
reactive T cells. Our data indicate that the primary mechanism by which PD-1 gene 
inactivation affects tumor-reactive T cells is by regulating their ability to survive 
rather than increasing their activity on a per cell basis, which aligns with the original 
description of the role of PD-1 signaling as a pro-apoptotic factor (8). Whilst we 
investigated PD-1 as the initial proof of concept target, the technology and approach 
described potentially allows the permanent disruption of one or more other inhibitory 
checkpoints, conferring a considerable advantage to the design the next generation of 
cancer immunotherapies.  
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Figure legends 
Fig. 1: TALEN-mediated PD-1 gene inactivation in pmel-1 CD8+T cells enhances 
the antitumor activity of ACT. (A) Schematic representation of murine Pdcd1 gene 
(chr. 1) and TALEN targeted sequence (exon 1). (B) TALEN protein expression at 
day 1, 2, 3 after transfection. (C) TALEN-induced mutagenesis (>50%) by Miseq 
analysis of CD8PD-1Ex1 pmel-1 T cells. NHEJ: non-homologous end joining. (D) B16 
tumor growth curve in mice receiving 1x106 CD8wt cells or CD8PD-1Ex1 ACT, 6 days 
after tumor challenge. (E) PD-1 expression on tumor-infiltrating CD8+ T cells and 
transferred cells engraftment at the tumor site. (F, G) Proliferation (KI67) and 
functional analysis of tumor-infiltrating CD8wt cells or CD8PD-1Ex1 depicting GZB and 
IFN- expressions. Each dot represents an individual mouse, and histograms represent 
mean ± SD of 2 independent experiments (n=10), two-way ANOVA (**P<0.01; 
***P<0.001). 
Fig. 2: Functional analysis of ACT with PD-1 gene inactivation on TRL 6 days 
after transfer in vivo. (A) Flow plots depicting PD-1 expression on TRLwt or TRLPD-
1-Ex1 T cells. (B) Percentage of PD-1- cells showing an average of 15-20% increase on 
TRLPD-1-Ex1 compared to TRLwt T cells. (C) Absolute number of PD1+ and PD1- 
TRLwt and TRLPD-1-Ex1 T cells per mg of tumor. (D, E, F) Representative flow plots 
showing KI67-, GZB- and IFN--expressions on CD4+ and CD8+ TRLwt and TRLPD-1-
Ex1 T cells and absolute number of cells per mg of tumor. Each dot plot represents an 
individual mouse, and histograms represent mean ± SD of 3 independent experiments 
(n=15). Non-parametric t test (B), two-way ANOVA (C, E, F) *P<0.05, **P<0.01, 
***P<0.001. 
Fig. 3: PD-1 regulates the survival of adoptively transferred TRL in vivo. (A, D) 
Representative histograms depicting the annexin-V/FLICA positivity in PD-1+ and 
PD-1- TRL 6 days after ACT. (B, E) Adjusted percentage of annexin-V+/FLICA+ 
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cells in PD-1+ and PD-1− subsets of CD4+ and CD8+ TRLwt and TRLPD-1Ex1T cells. 
Histograms represent mean ± SD from 2 independent experiments (n=10). (C, F) 
Absolute numbers of annexin-V-/FLICA- CD4+ and CD8+ TRL per mg of tumor. 
Two-way ANOVA (B), and multiple comparison one-way ANOVA with Bonferroni 
correction (C) **P<0.01, ***P<0.001. 
Fig. 4: Therapeutic efficacy of ACT with PD-1 gene inactivation of TRL on 
MCA205 fibrosarcoma. (A) MCA205 growth curve after ACT with TRL and CD8 
depleting or MHC-II blockade antibodies. Two-way ANOVA *P<0.05, **P<0.01. (B) 
Treatment with TRLPD-1Ex1 resulted in significant prolongation of survival (n=15). 
Log-rank test, P=0.0052. Depletion of CD8+ subset or MHC-II blockade abrogates the 
TRLPD-1Ex1 cells–induced antitumor effects (n=10).  
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